Aspire Biopharma's BUZZ BOMBTM Partners with EoS Fitness to Empower High-Performance Lifestyles for Millions of Members
Rhea-AI Summary
Aspire Biopharma (Nasdaq:ASBP) announced that subsidiary Buzz Bomb Caffeine Company has entered a strategic partnership with EoS Fitness, a high-value, low-price gym chain with more than 225 locations open or planned nationwide.
Through the EoS Flex Deals affiliate program, BUZZ BOMB™ 50mg sublingual caffeine stick packs gain exposure to millions of health-focused members, supported by over 80 million impressions in 2025 via in-gym TV, mobile app offers and on-site demos.
Positive
- Access to EoS Fitness network of more than 225 gym locations
- Exposure through EoS Flex Deals program with over 80 million impressions in 2025
- Expanded distribution for 50mg BUZZ BOMB caffeine stick packs to gym-focused consumers
Negative
- None.
News Market Reaction – ASBP
In the May 27 session, ASBP declined 7.89%, reflecting a notable negative market reaction. Argus tracked a peak move of +8.6% during that session. Argus tracked a trough of -27.6% from its starting point during tracking. Our momentum scanner triggered 17 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Partnership Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 15 | Retail partnership | Positive | -54.2% | Buzz Bomb hires Interwest to accelerate BUZZ BOMB retail distribution expansion. |
| Mar 03 | R&D partnership | Positive | +1.4% | Partnership with Microsize to develop rapid-delivery sublingual alprazolam powder. |
| Feb 03 | Distribution deal | Positive | -4.1% | Buzz Bomb partners with Blue Shark Beverages to expand Southern California placement. |
| Nov 06 | Partner outreach | Positive | -23.9% | Engagement with global pharma at CPHI Frankfurt on sublingual high-dose aspirin. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Partnership announcements have often been followed by negative price reactions despite constructive strategic content.
Recent partnership-related news for Aspire centers on BUZZ BOMB™ distribution and pharmaceutical collaborations. In Feb 2026, Buzz Bomb partnered with Blue Shark Beverages to expand Southern California distribution, and in Apr 2026 it engaged Interwest Brokerage for broader retail expansion across several Western states. Separately, Aspire formed a strategic partnership with Microsize to develop a rapid-delivery sublingual alprazolam powder with a planned Phase 1 trial in mid-2026. An earlier Nov 6, 2025 update highlighted partnering discussions for its sublingual high-dose aspirin based on positive investigational results.
Key Terms
sublingual medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
ESTERO, FL / ACCESS Newswire / May 27, 2026 / Aspire Biopharma Holdings, Inc.'s (Nasdaq:ASBP) ("Aspire" or the "Company") wholly owned subsidiary Buzz Bomb Caffeine Company LC is proud to announce a strategic partnership with EoS Fitness, the High Value. Low Price.® (HVLP) gym chain with more than 225 locations open or on the way nationwide. Through the EoS Flex Deals affiliate program, BUZZ BOMB™ 's lineup of 50mg sublingual caffeine stick packs will now be available to an expansive community of health-conscious gym members.
The EoS Flex Deals affiliate program is a premier partnerships platform designed to connect members with brands aligned with the EoS mission. With over 80 million impressions in 2025, the program provides BUZZ BOMB™ with a powerful ecosystem to drive engagement, brand visibility and revenue, via in-gym TV advertising, Flex Deal mobile app offers and on-site product demonstrations.
Unlike traditional energy drinks or pills, BUZZ BOMB™ is a new and exciting caffeine product delivered in a single-serving stick pack of dry powder sprinkled under the tongue. This method provides flavored caffeine quickly without the hassle of mixing with water or consuming typical caffeine sources like energy drinks, coffee, or soda.
Buzz Bomb Caffeine Company will be rolling out a variety of marketing initiatives and
collaborative content that maximizes awareness, including in-club digital assets, web
features, member communication and more.
"Partnering with EoS Fitness to bring our caffeine product to millions of members is a pivotal step for BUZZ BOMB™," said Kraig Higginson, CEO of Aspire. "We're meeting our customers where they are - in a premium environment that reflects their commitment to an intentional, high-performance lifestyle. By integrating our high-efficacy products into the EoS Fitness experience, we are empowering members to achieve peak performance, inside and out."
BUZZ BOMBTM Caffeine Products
BUZZ BOMB™ features 50mg of caffeine and is currently offered in four delicious flavors: Tropical Fruit, Mixed Berry, Peach Mango, and Coffee Mocha. Designed for athletes, professionals, and the everyday person needing a rapid boost, BUZZ BOMB™ provides a precise serving of caffeine in easy-to-use single serving stick packs.
To learn more about BUZZ BOMB™, or purchase products online, please visit
https://buzzbombcaffeine.com or follows us on social media here:
About Aspire Biopharma Holdings, Inc.
Aspire Biopharma delivers supplements to the body rapidly and precisely.
For more information, please visit www.aspirebiolabs.com
Aspire Biopharma Holdings, Inc.
Contact:
PCG Advisory
Kevin McGrath
+1-646-418-7002
kevin@pcgadvisory.com
Safe Harbor Statement
This press release contains "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the "safe harbor" provisions created by those laws. Aspire's forward-looking statements include, but are not limited to, statements regarding our or our management team's expectations, hopes, beliefs, intentions or strategies regarding our future operations. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words "anticipate," "believe," "contemplate," "continue," "estimate," "expect," "intends," "may,""might," "plan," "possible," "potential," "predict," "project," "should," "will," "would," and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements represent our views as of the date of this press release and involve a number of judgments, risks and uncertainties. We anticipate that subsequent events and developments will cause our views to change. We undertake no obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date. As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ in our drug or supplement offerings include general market conditions, whether clinical trials demonstrate the efficacy and safety of our drug candidates to the satisfaction of regulatory authorities, or do not otherwise produce positive results which may cause us to incur additional costs or experience delays in completing, or ultimately be unable to complete the development and commercialization of our drug candidates; the clinical results for our drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of
clinical trials and marketing approval; our ability to achieve commercial success for our drug or supplement candidates, if approved; our limited operating history and our ability to obtain additional funding for operations and to complete the development and commercialization of our product candidates, and other risks and uncertainties set forth in "Risk Factors" in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q. In addition, statements that "we believe" and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to rely unduly upon these statements. All information in this press release is as of the date of this press release. The information contained in any website referenced herein is not, and shall not be deemed to be, part of or incorporated into this press release.
SOURCE: Aspire Biopharma Holdings, Inc.
View the original press release on ACCESS Newswire